ZURICH, Switzerland and BOSTON, May 8 /PRNewswire/ -- ESBATech AG, a developer of fully-human antibody fragment therapeutics, today announced that Dominik Escher, Ph.D., Vice Chairman and Chief Executive Officer, will make an investor presentation at the Rodman & Renshaw 3rd Annual Global Healthcare Conference.
The Conference will take place at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco, on May 15-16, 2006. Dr. Escher’s presentation will take place on Monday, May 15, at 9:45 a.m. CEST time, in the Zephyr Salon (4th floor). Dr. Escher will be available for one-on-one meetings during the conference. is a full service investment bank. For more information about Rodman & Renshaw conferences, visit http://www.rodmanandrenshaw.com/conferences.
About ESBATech AG
Privately-held ESBATech is a Zurich, Switzerland-based drug discovery and development company focused on advancing antibody fragment therapeutics for inflammatory applications. Current venture investors include Novartis Venture Fund, BioMedinvest, Venture Incubator, BSI, Difasa, Network Capital and Management. The Company is currently raising additional venture financing in the US and Europe. ESBATech was founded in September 1998 and currently has 30 employees. For more information about ESBATech, please visit http://www.esbatech.com.
Contacts: Media: Investor: Bryan P. Murphy Donna LaVoie LaVoie Group LaVoie Group (781) 596-0200 X105 (781) 596-0200 X103 bmurphy@lavoiegroup.comdlavoie@lavoiegroup.com
ESBATech AG
CONTACT: Media: Bryan P. Murphy, +1-781-596-0200 ext. 105,bmurphy@lavoiegroup.com, or Donna LaVoie, +1-781-596-0200 ext. 103,dlavoie@lavoiegroup.com, both of LaVoie Group for ESBATech AG
